Latest research on Nexium

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]

Nexium interactions

One hour prior to FMT, patients were given Metoclopramide 10 mg by intramuscular injection and Esomeprazole Magnesium 40 mg intravenously to promote motility of the transplanted microbiota into the colon and to inhibit the secretion of gastric acid [13]. [source, 2015]
PPIs with brand name only formulations available for the entire study period (2006–2010) included esomeprazole (Nexium), Rabeprazole (Aciphex), omeprazole/sodium bicarbonate (Zegerid), and dexlansoprazole (Dexilant). [source, 2015]
Metformin HCl, Ciprofloxacin HCl, and Esomeprazole Sodium were respectively purchased from Flame Pharmaceuticals (Andhra Pradesh, India), Neuland Laboratories (Andhra Pradesh, India), and Glenmark Generics (Bharuch Gujarat, India). [source, 2015]
Providing further examples, PharmaInformatic released a report describing how several blockbuster drugs, including aripiprazole (Abilify) and esomeprazole (Nexium), showed low oral bioavailability in animals. [source, 2015]
Logistic regression (including inpatient plus initial features) resulted in the optimum rule using inpatient plus ED features with eight clinical weighted features associated with HO-HCFA designated by the mnemonic CLEAN OFF–CDI: CDI history – 14 points, Lives in assisted living facility – 9 points, Elevated WBC count (> 8800 cells/mm3) - 3 points, Antibiotic use during admission – 3 points, Nexium like medicine [proton pump inhibitor] use during admission – 5 points, Operation during admission – 4 points, Fasting blood sugar high (history of diabetes) - 2 points, and a Faulty immune system – 4 points. [source, 2015]
The patients were using DPIs delivering a combination of Budesonide and formoterol, either Symbicort (AstraZeneca, Lund, Sweden) or Alenia (Aché Laboratórios Farmacêuticos S.A. [source, 2015]
(Seoul, Republic of Korea) as a tablet combining Esomeprazole Strontium (20 mg), which is immediately released in the stomach, and enteric-coated Naproxen (500 mg), which is released later in the small intestine. [source, 2015]
HCP1004 contains Esomeprazole Strontium, which is a new formulation of esomeprazole that incorporates a strontium salt rather than a Magnesium salt. [source, 2015]
VIMOVO® contains Esomeprazole Magnesium. [source, 2015]
The efficacy of esomeprazole strontium has been established in a previous study, as the bioequivalence of the proposed product to the reference product (Esomeprazole Magnesium) has been demonstrated. [source, 2015]